Document Detail


Safety of botulinum toxin type A in children younger than 2 years.
MedLine Citation:
PMID:  19036619     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Botulinum toxin type A (BoNT-A) has been used in many indications and is licensed for the treatment of spasticity in children older than 2 years. However, there are few reports of BoNT-A treatment in patients younger than 2 years of age. AIMS: To review retrospectively the safety data from all infants treated with botulinum toxin type A (BoNT-A) before 2 years of age in a paediatric neurology unit. METHODS: There were 74 infants: 28 received the first dose before 1 year of age, and 46 between the ages of 1 and 2 years. RESULTS: In the first year of life, the most frequent indication was obstetric brachial palsy (OBP) (71.4% of cases) and in the second year, cerebral palsy (CP) (73.9%). Both Botox and Dysport, the two commercially-available BoNT-A products in Spain, were used. The average starting dose by session was 6.55 U/kg body weight Botox in infants in their first year of life, and 8.4 U/kg body weight Botox and 21.1 U/kg body weight Dysport in the second year of life. Only 3.6% of cases treated in the first year and 6.5% of those treated in the second experienced adverse events (AEs), which consisted of mild weakness or tiredness lasting 1-4 days. CONCLUSIONS: BoNT-A has a good safety profile in infants younger than 2 years old. AEs are similar to those found in older children.
Authors:
Samuel Ignacio Pascual-Pascual; Ignacio Pascual-Castroviejo
Related Documents :
17146199 - Periventricular leukomalacia with late-onset circulatory dysfunction of premature infan...
3900799 - Periventricular leukomalacia: a correlation study between real-time ultrasound and auto...
10735459 - The role of cortical evoked responses in predicting neuromotor outcome in very preterm ...
976279 - Analysis of etiologic factors in cerebral palsy with severe mental retardation. i. anal...
9521949 - Trends in mortality and cerebral palsy in a geographically based cohort of very low bir...
9608889 - Magnesium sulfate and cerebral palsy in premature infants.
3752079 - Empirical validation of the essen-möller probability of paternity.
3821059 - An automatic feeder for infant rats.
20576369 - Intrauterine growth restriction in a low-income country: risk factors, adverse perinata...
Publication Detail:
Type:  Journal Article     Date:  2008-11-25
Journal Detail:
Title:  European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society     Volume:  13     ISSN:  1532-2130     ISO Abbreviation:  Eur. J. Paediatr. Neurol.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-11-02     Completed Date:  2010-01-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9715169     Medline TA:  Eur J Paediatr Neurol     Country:  England    
Other Details:
Languages:  eng     Pagination:  511-5     Citation Subset:  IM    
Affiliation:
Pediatric Neurology Service, University Hospital La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain. ipascualp.hulp@salud.madrid.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Botulinum Toxin Type A / adverse effects*,  therapeutic use
Cerebral Palsy / drug therapy
Drug Toxicity / chemically induced*
Humans
Infant
Neuromuscular Agents / adverse effects*,  therapeutic use
Paralysis, Obstetric / drug therapy
Retrospective Studies
Severity of Illness Index
Spain
Spasm / drug therapy
Treatment Outcome
Chemical
Reg. No./Substance:
0/Botulinum Toxin Type A; 0/Neuromuscular Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The predictive validity of general movements--a systematic review.
Next Document:  Comparison between weight-based and IGF-I-based growth hormone (GH) dosing in the treatment of child...